Excerpt: QUELIMMUNE is approved in a narrow pediatric setting, but the bigger value driver is whether SeaStar can extend its selective cytopheretic device into the much larger adult AKI market — and whether the balance sheet can fund the wait. The hub covers the technology, the commercial-adoption progress so far, the adult-AKI pathway and the cash/dilution risk, updated over time.
Full write-up (free, no signup): https://www.merlintrader.com/seastar-medical-...stock-hub/
Not financial advice — just research.